Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G W Muller

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 1999
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alphaL G Corral, P A Haslett, G W Muller, et al.
Cellular Signalling|June 3, 2014
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunityP H Schafer, A Parton, L Capone, et al.
Plant Disease|February 24, 2019
First Report of the Causal Agent of Huanglongbing ("Candidatus Liberibacter asiaticus") in BrazilH D Coletta-Filho, M L P N Targon, M A Takita, et al.
British Journal of Cancer|March 5, 2004
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancersJ B Bartlett, A Michael, I A Clarke, et al.
British Journal of Pharmacology|January 7, 2010
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisP H Schafer, A Parton, A K Gandhi, et al.
Blood|June 22, 2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaF E Davies, N Raje, T Hideshima, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Journal of Immunology (Baltimore, Md. : 1950)|June 29, 1999
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alphaL G Corral, P A Haslett, G W Muller, et al.
Cellular Signalling|June 3, 2014
Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunityP H Schafer, A Parton, L Capone, et al.
Plant Disease|February 24, 2019
First Report of the Causal Agent of Huanglongbing ("Candidatus Liberibacter asiaticus") in BrazilH D Coletta-Filho, M L P N Targon, M A Takita, et al.
British Journal of Cancer|March 5, 2004
Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancersJ B Bartlett, A Michael, I A Clarke, et al.
British Journal of Pharmacology|January 7, 2010
Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasisP H Schafer, A Parton, A K Gandhi, et al.
Blood|June 22, 2001
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaF E Davies, N Raje, T Hideshima, et al.
Pageof 2